The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M(2) receptor subtype

Triple negative tumors are more aggressive than other breast cancer subtypes and there is a lack of specific therapeutic targets on them. Since muscarinic receptors have been linked to tumor progression, we investigated the effect of metronomic therapy employing a traditional anti-cancer drug, pacli...

Descripción completa

Detalles Bibliográficos
Autores principales: Español, Alejandro J., Salem, Agustina, Di Bari, María, Cristofaro, Ilaria, Sanchez, Yamila, Tata, Ada M., Sales, María E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482849/
https://www.ncbi.nlm.nih.gov/pubmed/32911509
http://dx.doi.org/10.1371/journal.pone.0226450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482849/
https://www.ncbi.nlm.nih.gov/pubmed/32911509
http://dx.doi.org/10.1371/journal.pone.0226450

Ejemplares similares